Figure 1: Characterisation of a novel monoclonal antibody, DTE41, targeting glutamylated Δ2 form of α-tubulin. | Scientific Reports

Figure 1: Characterisation of a novel monoclonal antibody, DTE41, targeting glutamylated Δ2 form of α-tubulin.

From: Increase in α-tubulin modifications in the neuronal processes of hippocampal neurons in both kainic acid-induced epileptic seizure and Alzheimer’s disease

Figure 1

(a) Antigen used to generate mAb DTE41. The C-terminal part of Δ2 form with di-glutamylation was used. Colour codes of the rod structure of antigen peptide are green, carbohydrate chain in Δ2 form; yellow, carbohydrate chain of branched di-glutamates; blue, nitrogen; red, oxide. The peptide has in total 8 carboxyl groups. (b) Schematic view of recombinant α-tubulin tail fused to maltose binding protein (MBP) with different C-terminal modifications, tyrosination (Tyr), detyrosination (deTyr), and Δ2 form. Epitope of DM1A is indicated. (c) Preference of mAb DTE41 to Δ2-tubulin. Recombinant α-tubulin C-termini with different modifications were subjected to immunoblotting. Original full-length blot images were provided in Supplementary Figure 6a. (d) Schematic view of peptides used for ELISA. (e) ELISA of mAb DTE41 against peptides shown in panel d.

Back to article page